every point exactly, @JasAWebb - easy to feel defeated hearing this news, but will take that energy and use it to inspire action towards the many challenges that face us...

🎉🎉 Congratulations to Barbara Alexander, who will be the new president of IDSA. "The critical role of ID physicians & scientists has never been more apparent as it is today." idsociety.org/news--publicat…

Outcome of #Hodgkin arising from #CLL. collaboration led by Deborah Stephens. haematologica.org/article/view/h… Danielle M. Brander Matthew Davids, MD, MMSc @anthonymatomd Fred Hutch Cancer Center @SeattleCCA

Please see our publication of the largest cohort of patients #Hodgkin transformation in #CLL patients. haematologica.org/article/view/h… Planning more research in this patient population. Thanks for a great collaborative effort. Huntsman Cancer Institute University of Utah. University of Utah Health

We are so excited to welcome Joyce Hwang Andrew M. Peseski, DO Fahmin Basher, MD, PhD Drs. Kathrine DiNardo, Cameron Oswalt, Grayce Selig, and Cameron Wood to the Duke Heme/Onc Fellowship Program! We are so excited to have you join our wards and clinics in July 2021! Duke Cancer Duke Department of Medicine

Intolerance is a failure of the medication for that given patient, patients don’t fail therapy. Grateful to be a part of this collaborative effort Duke Hematologic Malignancies & Cellular Therapy and for all trials aimed at the unmet need of intolerance. @anthonymatomd Andrea Sitlinger and many others

To teach is to learn, twice And thankful for this opportunity from #ASH20, twice - to learn from so many others but also to work on this with an amazing fellow Duke HemeOnc Fellows, Dr Ashley Hanlon Ashley, that has taught me so much and co authored this chapter #dukefamily

#ASH20 poster by Lindsay Rein Duke Hematologic Malignancies & Cellular Therapy Duke Department of Medicine Duke Cancer Phase I trial incorporating NK cells for patients w/ #CML & MRD after TKI therapy. #leusm bit.ly/3osWQ7x

There may not have been an official ASH run this year, but anyone else still get in their #FauciFour ? If daily running is the secret to Dr Fauci leading the nation through this chaos, may I never stop. Also, the San Diego skyline has nothing on my view. #IRunForASH

Important MURANO tox ax @anthonymatomd Jeff Sharman et al 28% premature d/c VR<2y ⬇️ PFS in prem d/c ven for any reason (PD excluded;p<0.0001)+due to AE Interrupt for AE 69% / dose ⬇️ 23% both no impact on PFS/OS Tox mx+continued Rx important for VenR PFS outcome #CLL #lymsm

Thanks to the CLL Society Inc. for all you do for our patients. Happy New Year!

Just out - our multicenter effort to dissect comorbidities in CLL ⁦Mazyar Shadman, MD MPH⁩ ⁦Daniel Persky, MD⁩ ⁦Danielle M. Brander⁩ ⁦Matthew Mei⁩ ⁦Jonathon Cohen MD MS⁩ ⁦Krish Patel⁩ ⁦Brian Hill⁩ ⁦Deborah Stephens⁩ clincancerres.aacrjournals.org/content/early/…

Outstanding commentary by ⁦Deborah Stephens⁩ from ⁦Huntsman Cancer Institute⁩ on the recent publication on the ELEVATE-RR study comparing ibrutinib and acalabrutinib in R/R CLL in ⁦Journal of Clinical Oncology⁩ ascopubs.org/doi/abs/10.120…

Ask your doctor if you are considered high risk by the CLLIPI score. If so, you may qualify for this exciting study. #CLL SWOG Cancer Research Network Brian Hill Mazyar Shadman, MD MPH @anthonymatomd Danielle M. Brander Danilov Lab

CME Opportunity: Join #DukeDebates2024, presented by #DukeCancerNetwork in collaboration with Duke Cancer. April 12-14, 2024, Hilton Head, SC Register here: bit.ly/DukeDebates CME credit available. Earn up to 12 MOC Part 2 points. #DukeCancerInstitute #MedEd